Ajay Vishwakarma

✨It was a pleasure to see our Founder CEO, Dr. Ajay Vishwakarma speak last Wednesday at Biolabs@NYULangone, alongside inspiring leaders and innovators at the intersection of breakthrough science and capital.

Thank you to all the speakers, moderators, and everyone who joined us:

Cell BioEngines Announces Establishment of New R&D Facility to Further Advance Its Platform and Pipeline of Innovative Cell Therapies Cell BioEngines Joins Center for Engineering and Precision Medicine (CEPM), Expands Relationship with Mount Sinai...

Exciting News! 🎉 We are thrilled to announce the newest funding from and EmpireStateDevelopment !

Derisking early stage, deep-tech therapeutics venture investment in these difficult times is as hard if not harder than founders building the company from zero to one.

Congrats to Cell BioEngines, Inc team backed by SOSV for making it to the 2024 Human Heath 100 with second round of investment. Hoping for biotech’s rapid recovery!

Announcing the 2024 Human Health 100 Welcome to the third annual SOSV Human Health 100. The list features SOSV’s 100 most exciting companies in the health category, which for SOSV ranges very widely, from assistive robotics and remote care to therapeutics and diagnostics. In the past two years (see the 2023 and 2022 lists), venture....

Cell BioEngines, Inc moves to Manhattan, New York, to leverage the city’s focus and strategic investment in biotech

Cell BioEngines Licenses Patent for Allogeneic Hematopoietic Cell Transplantation in Oncology

Cell BioEngines Licenses Patent for Allogeneic Hematopoietic Cell Transplantation in Oncology Small molecule-mediated expansion of engraftable cord-blood derived hematopoietic stem cells (HSC) to address donor availability for allogenic hematopoietic stem cell transplant Cell BioEngines, Inc and Icahn Mount Sinai Icahn Mount Sinai’s Dr. Ronald Hoffman and Cell BioEngines Founder and CEO Dr...